中国医院用药评价与分析2019，Vol.19Issue(2)：188-189,191,3.DOI:10.14009/j.issn.1672-2124.2019.02.021
沙格列汀联合二甲双胍治疗2型糖尿病的疗效观察
Observation on Efficacy of Saxagliptin Combined with Metformin in Treatment of Type Ⅱ Diabetes Mellitus
谈凤联 1林达秋2
作者信息
- 1. 广州中医药大学顺德医院内分泌科, 广东 佛山 528300
- 2. 广州中医药大学顺德医院三门诊, 广东 佛山 528300
- 折叠
摘要
Abstract
OBJECTIVE: To probe into the efficacy of saxagliptin combined with metformin in treatment of type Ⅱ diabetes mellitus. METHODS: 200 patients with type Ⅱ diabetes mellitus admitted into Shunde Hospital of Guangzhou University of Chinese Medicine from Jun. 2017 to Jun. 2018 were selected and randomly divided into control group and observation group, with 100 cases in each. The control group was treated with metformin, while the observation group was given saxagliptin combined with metformin. The clinical efficacy, incidences of adverse drug reactions, blood glucose levels [fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 hPG) and glycosylated hemoglobin (HbA1c) ] can body mass index (BMI) of two groups were observed. RESULTS: The total effective rate of observation group was 92.0％ (92/100), which was significantly higher than that of the control group (72.0％, 72/100), with statistically significant difference (P＜0.05); the incidence of adverse drug reactions of observation group was 4.0％ (4/100), which was significantly lower than that of the control group (12.0％, 12/100), with statistically significant difference (P＜0.05); after treatment, the FPG, 2 hPG, HbA1c and BMI levels of observation group were significantly better than that of the control group, with statistically significant differences (P＜0.05). CONCLUSIONS: The efficacy of saxagliptin combined with metformin in treatment of type Ⅱ diabetes mellitus is remarkable and more significant than that of metformin alone, which can control patients' blood glucose and BMI, with few adverse drug reactions and high safety.关键词
二甲双胍/2型糖尿病/沙格列汀Key words
Metformin/Type Ⅱ diabete mellitus/Salgletine分类
医药卫生引用本文复制引用
谈凤联,林达秋..沙格列汀联合二甲双胍治疗2型糖尿病的疗效观察[J].中国医院用药评价与分析,2019,19(2):188-189,191,3.
